Feb. 15, 2005 — Researchers have long looked for a way to treat diabetes using transplants. Early success of a single-donor islet transplantislet transplant in treating type 1 diabetes may bring the promise of the exploratory diabetes treatment one step closer to reality.
A unused think about showed that eight individuals with sort 1 diabetes who received an islet transplant from a single cadaver giver now not required insulin injections one year later, and five of the transplant recipients now not required them for more than one year.
Individuals with sort 1 diabetes cannot make insulin to control blood sugar levels and must take affront infusions to preserve healthy blood sugar levels.
Islets are insulin-producing cells found within the pancreas. In spite of the fact that islet transplants have shown much guarantee in allowing individuals to gain freedom from insulin therapy, current methods require transplanting a better number of islets from two to four donor pancreases.
Analysts say in arrange for islet transplants to become a reality in treating type 1 diabetes, extra propels are required, such as requiring as it were one donor pancreas to reduce dangers and costs and to increase the availability of islet cells.
Islet Transplants Inch Closer to Reality
In the ponder, researchers examined the security and adequacy of single-donor islet transplant. The comes about show up within the Feb. 16 issue of The Journal of the American Therapeutic Affiliation.
In order to extend the chances of victory, researchers took steps to decrease harm to islet cells whereas the giver pancreas was in storage. They also required that recipients utilize immunotherapy drugs some time recently transplantation to assist avoid their safe systems from dismissing the cells.
The islet transplants were conducted from July 2001 to Eminent 2003 in eight women with type 1 diabetes.
The results appeared that the transplanted islets were able to distinguish blood sugar levels and secrete insulin in all eight single-donor islet transplant recipients, freeing them from affront injections.
Five of the beneficiaries remained insulin independent for longer than one year.
No serious or startling side effects were associated with the islet transplants.
Analysts say this early success with a single-donor islet transplant procedure could be a major progress but encourage study in a larger group of individuals with type 1 diabetes over a longer period of time is required.